|
Sep 2, 2004 |
NEW HAVEN, Conn. September 2, 2004 —Achillion
Pharmaceuticals, Inc., a leader in the discovery and development of small molecule
drugs to combat the most challenging of infectious diseases, today announced
the appointment of Michael D. Kishbauch as Chief Executive Officer. Mr. Kishbauch
replaces interim CEO, Marios Fotiadis. Ac...
|
|
|
Oct 13, 2004 |
NEW HAVEN, Conn. October 13, 2004 —Achillion
Pharmaceuticals, Inc., a leader in the discovery and development of small
molecule drugs to combat the most challenging of infectious diseases, today
announced
the appointment of Gautam Shah, Ph.D. to the position of Vice President,
Regulatory Affairs. Dr. Shah brings over sixteen year...
|
|
|
Nov 29, 2004 |
Foster City, CA and New Haven, CT, November
29, 2004 — Gilead Sciences (Nasdaq: GILD) and Achillion
Pharmaceuticals today announced that the
companies have signed an exclusive agreement granting Gilead worldwide
rights for the research, development and commercialization of certain
Achillio...
|
|
|
Mar 23, 2005 |
New Haven, CT, March 23, 2005 — Achillion
Pharmaceuticals, Inc., a leader in the discovery and development of small
molecule drugs to combat the most challenging infectious diseases, today
announced two management promotions. Milind S. Deshpande, Ph.D. was named
Chief
Scientific Officer an...
|
|
|
May 2, 2005 |
New Haven, CT, May 2, 2005 — Achillion
Pharmaceuticals Inc., today announced that the Company has received a
Phase 1 Small Business Innovation Research Grant (SBIR) from the National
Institute of Allergy and Infectious Disease (NIAID) branch of the National
Institutes of Health (NIH). The grant cov...
|
|
|
Aug 15, 2005 |
Foster City, CA and New Haven, CT, August
15, 2005 —Gilead Sciences (Nasdaq: GILD) and Achillion
Pharmaceuticals today announced that the companies have begun dosing patients
in a Phase I study of GS 9132, also known as ACH-806. Gilead and Achillion
are investigating GS 9132 for the treatment o...
|
|
|
Sep 22, 2005 |
New Haven, CT, September 22, 2005
— Achillion Pharmaceuticals, Inc., a leader in the discovery and
development of small molecule drugs to combat the most challenging infectious
diseases, today announced that Michael D. Kishbauch, Chief Executive Officer
of Achillion will be presenting a corpora...
|
|
|
Nov 4, 2005 |
New Haven, CT, November 4, 2005
— Achillion Pharmaceuticals, Inc., a leader in the discovery and
development of small molecule drugs to combat the most challenging infectious
diseases, today announced that Michael D. Kishbauch, Chief Executive Officer
of Achillion, will be presenting a corporat...
|
|
|
Apr 3, 2006 |
New Haven, Conn, April 3, 2006
— Achillion Pharmaceuticals, Inc., announced today that it has filed
a registration statement on Form S-1 with the Securities and Exchange Commission
relating to the proposed initial public offering of shares of its common
stock. All shares of the common stock to be sold ...
|
|
|
Oct 26, 2006 |
New Haven, Conn., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the pricing of its initial public offering of 4,500,000 shares of its common stock at $11.50 per share, before underwriting discounts and commissions. All of the common stock is being offered by Achillion. ...
|
|
